Axel Merseburger
Axel Merseburger, MD, PhD
Axel Merseburger is Professor of Urology and Chairman of the Department of Urology at University Hospital Schleswig-Holstein, Campus Lübeck, Germany. He studies biomarkers and prognostic factors for prostate cancer, renal cell carcinoma, and transitional cell carcinoma. He is Editor-in-Chief of the European Journal of Haematology and Oncology and Aktuelle Urologie.
Disclosures: Lectures/speaker/honoraria: Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, Eisai, Ferring, Ipsen, Janssen, Merck Serono, MSD, Novartis, Pfizer, Recordati, Roche, Takeda, and Teva. Consultancy: Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, EUSA Pharma, Ferring, Ipsen, Janssen, Merck Serono, MSD, Novartis, Pfizer, Recordati, Roche, Takeda, and Teva. Research and clinical trials: Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, EUSA Pharma, Ipsen, Janssen, Merck Serono, MSD, Novartis, Pfizer, Roche, Takeda, and Teva.
View content featuring Merseburger:
• Roundtable: mCRPC update 2024
This content has been developed independently by Medthority who previously received educational funding from Pfizer in order to help provide its healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content.
of interest
are looking at
saved
next event